HC Wainwright Cuts Earnings Estimates for Sutro Biopharma

Sutro Biopharma, Inc. (NASDAQ:STRO) – Equities researchers at HC Wainwright decreased their Q1 2026 EPS estimates for Sutro Biopharma in a research report issued to clients and investors on Tuesday, March 24th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($2.53) per share for the quarter, down from their previous estimate of ($1.54). HC Wainwright has a “Buy” rating and a $28.00 price target on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($2.92) per share. HC Wainwright also issued estimates for Sutro Biopharma’s Q2 2026 earnings at ($2.58) EPS, Q3 2026 earnings at ($2.59) EPS, Q4 2026 earnings at ($2.62) EPS, FY2026 earnings at ($10.32) EPS, FY2027 earnings at ($8.27) EPS, FY2028 earnings at ($8.06) EPS and FY2029 earnings at ($5.63) EPS.

Other equities analysts also recently issued reports about the stock. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Sutro Biopharma from $51.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday. Citigroup upgraded Sutro Biopharma to an “outperform” rating in a report on Tuesday, January 20th. Citizens Jmp raised Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 price target for the company in a research report on Tuesday, January 20th. Truist Financial raised Sutro Biopharma to a “strong-buy” rating in a research report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $37.29.

Sutro Biopharma Trading Down 0.3%

Shares of STRO stock opened at $23.50 on Thursday. Sutro Biopharma has a 1 year low of $5.23 and a 1 year high of $26.54. The firm’s fifty day moving average price is $18.61 and its two-hundred day moving average price is $12.76. The firm has a market capitalization of $199.99 million, a P/E ratio of -0.90 and a beta of 1.47.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of STRO. Velan Capital Investment Management LP grew its holdings in Sutro Biopharma by 2.0% during the 3rd quarter. Velan Capital Investment Management LP now owns 3,120,000 shares of the company’s stock worth $2,709,000 after acquiring an additional 60,000 shares during the last quarter. UBS Group AG raised its stake in shares of Sutro Biopharma by 14.0% during the third quarter. UBS Group AG now owns 1,845,839 shares of the company’s stock valued at $1,602,000 after acquiring an additional 226,955 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of Sutro Biopharma by 1,052.8% during the first quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock worth $859,000 after purchasing an additional 1,206,330 shares during the period. Jane Street Group LLC bought a new stake in shares of Sutro Biopharma in the second quarter worth $492,000. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Sutro Biopharma in the third quarter valued at $387,000. Institutional investors own 96.99% of the company’s stock.

Key Stories Impacting Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Deutsche Bank raised its price target on STRO to $55 (from $51) and kept a Buy rating — a materially higher target that suggests strong upside vs. the current share price and supports bullish investor expectations. Deutsche Bank raises PT to $55
• Positive Sentiment: Wells Fargo upgraded STRO from Equal Weight to Overweight and raised its price target to $27 (from $8), signaling improving institutional sentiment and providing a nearer-term upside anchor for the stock. Wells Fargo upgrade
• Positive Sentiment: HC Wainwright upgraded STRO from Neutral to Buy and raised its target to $28 (from $10). The firm also published FY2030 EPS projections (large negative EPS expected), but maintained a Buy stance and higher target — a supportive signal from a biotech-focused shop. HC Wainwright upgrade HC Wainwright EPS note
• Neutral Sentiment: Short-interest reports for March show anomalous values (reported as 0 shares with NaN changes and 0.0 days-to-cover across different volume baselines). The data appears unreliable or reflects a reporting/clearing event, so its immediate impact on price is unclear. (Multiple internal short-interest notices consolidated)

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.